ArticleJournal of health, population, and nutrition2025
Impact of national volume-based procurement policy on drugs treating chronic Myelogenous Leukemia.
Article in Journal of health, population, and nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Strategies to Overcome Inequities in the Treatment of Patients with Hematologic Malignancies.Current hematologic malignancy reports · 2026Review
- Diagnosis-Related group payment and its impact on hospitalization costs and patient financial protection for neurointerventional stroke care in a Chinese tertiary hospital: a retrospective analysis.Cost effectiveness and resource allocation : C/E · 2026Article
- Impact of China's National Volume-Based Procurement Policy on the Affordability and Utilization of Tyrosine Kinase Inhibitors for Childhood Leukemia.Health data science · 2026Article
- Long-term trends in the burden of leukemia subtypes in China from 1990 to 2021: a Joinpoint regression and age-period-cohort analysis based on GBD 2021.Frontiers in medicine · 2026Article
- Impact of combined medication payment management policies on population health performance.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundTyrosine kinase inhibitors (TKIs) have been shown to improve survival rate in chronic myeloid leukemia (CML) patients, but their high costs impose a significant economic burden. This study aimed to evaluate the impact of China's National Volume-Based Procurement (NVBP) policy on the affordability, procurement volume, and costs of these drugs.
methodsBased on the data of drug procurement transactions in the database of China Health Insurance Bureau, this study analyzed the impact of National Volume-Based Procurement policy on the affordability, Defined Daily Doses (DDDs), expenditure, and Defined Daily Dose cost (DDDc) of three tyrosine kinase inhibitor (Imatinib, Nilotinib, and Dasatinib) in 25 provinces and hospitals of different levels from January 2019 to December 2020 in China by using an interrupted time series model.
resultsAfter the implementation of the procurement policy, the unit price of policy-related Imatinib decreased, leading to increased affordability and a rise of 146.9 thousand DDDs in the month of implementation (p < 0.05), while expenditure remained unchanged. The DDDs and expenditures for Nilotinib and Dasatinib did not show significant changes. The procurement volume of bid-winning generic Imatinib increased by 215.2 thousand DDDs in the month of policy implementation (p < 0.001), with usage share rising from approximately 40% to 80%. Conversely, the DDDs of non-bidding generic and originator drugs significantly decreased post-implementation. The DDDc of Imatinib reduced 69.5 in the month of NVBP implementation (p < 0.001). Furthermore, the DDDc of both bid-winning generic and non-bidding generic Imatinib significantly decreased in the month of policy implementation (p < 0.001).
conclusionsThe National Volume-Based Procurement policy effectively reduced the unit price of relevant drugs and increased their utilization, thereby improving drug affordability and reducing the financial burden on CML patients requiring long-term treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.